sEphB4-Alb mediated inhibition of Ephrin-B2/EphB4 signaling also results in areas of hypoxia in the tumor and increased expression of VEGF and Dll4 [17], which support the combined use of Ephrin-B2, VEGF, and Dll4 inhibitors. The gene discussed is ALB; the disease is neoplasm.